DELRAY BEACH, Fla., Jan. 26, 2005 (PRIMEZONE) -- Hard to Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announced today that the Federal Court heard oral argument on the Company's Motion for Partial Summary Judgment Against Defendants Shinn and Knight during a hearing held on January 20, 2005.
During the hearing before the Court, HTTD presented a concise overview of the facts and legal arguments, with reference to specific exhibits, to the Court. The Company's position has been consistent throughout this litigation. Defendants have presented three alternative and sometimes inconsistent responses to HTTD's claims. These claims, issues, defenses, and references to facts had been extensively briefed and filed with the Court prior to the hearing. The Federal Court carefully listened to the arguments and points of the Company and Defendants Shinn and Knight and advised the parties that it will review the Parties' briefs before issuing a ruling.
At the close of the hearing, the Court acknowledged that in many business-related disputes it is in the best interests of the parties to seek a negotiated resolution before trial. However, the Court noted that the parties may seek to move towards a trial as soon as practicable.
The Federal Judge's ruling will be posted on HTTD's website at: www.htdsotc.com and a press release issued as soon as the ruling is received.
Management's intention and goal with this litigation is to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders.
HTTD is currently involved in litigation regarding the rights to Tubercin (r). Additional information and details regarding the litigation can be viewed at our website at: www.htdsotc.com
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.